Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Severe Alopecia Areata
NCT06012240Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2023
- Primary completion
- Apr 2030
- Modality
- Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of upadacitinib in alopecia areata, sponsored by AbbVie Inc.. Started Oct 2023; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT06012240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06012240.